This episode explores the pivotal regulatory change in the United Arab Emirates allowing medical device manufacturers to appoint an independent Local Authorized Representative (LAR), decoupling registration from commercial distribution. We analyze the risks of the old distributor-as-LAR model and highlight the strategic advantages of the new system, including enhanced market flexibility, greater control over registrations, and improved business continuity for MedTech companies targeting the UAE. • Why was appointing a distributor as your LAR in the UAE a major business risk? • What specific change did the UAE's Ministry of Health and Prevention (MOHAP) implement regarding in-country representation? • How does an independent LAR give manufacturers more control over their products? • What are the key strategic benefits of separating regulatory compliance from commercial sales? • Can you appoint multiple distributors in the UAE after this change without re-registering your device? • What are the core responsibilities of an independent LAR? • How does this shift affect your ability to enter or scale within the UAE market? • Does the manufacturer or the LAR own the device registration under the new model? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.